Compare OPK & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OPK | TBPH |
|---|---|---|
| Founded | 2006 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 921.2M | 1.0B |
| IPO Year | 2011 | 2013 |
| Metric | OPK | TBPH |
|---|---|---|
| Price | $1.21 | $13.88 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | $2.03 | ★ $29.20 |
| AVG Volume (30 Days) | ★ 2.3M | 423.6K |
| Earning Date | 05-29-2026 | 06-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.88 |
| Revenue | ★ $606,879,000.00 | $15,386,000.00 |
| Revenue This Year | N/A | $70.90 |
| Revenue Next Year | $8.75 | N/A |
| P/E Ratio | ★ N/A | $21.42 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.11 | $7.90 |
| 52 Week High | $2.04 | $21.03 |
| Indicator | OPK | TBPH |
|---|---|---|
| Relative Strength Index (RSI) | 46.64 | 23.46 |
| Support Level | $1.12 | $13.58 |
| Resistance Level | $1.27 | $14.76 |
| Average True Range (ATR) | 0.04 | 0.97 |
| MACD | 0.01 | -0.41 |
| Stochastic Oscillator | 60.71 | 12.70 |
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment.
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).